JPRN-jRCT2031260310 Alixorexton Narcolepsy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Move from a broad disease map to a decision-ready trial dossier. This focused report examines JPRN-jRCT2031260310—A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.
Why JPRN-jRCT2031260310 is a hot trial to watch
Narcolepsy is increasingly segmented by mechanism, biomarker, line of therapy, geography and endpoint architecture. JPRN-jRCT2031260310 is notable because it tests Alixorexton in a Phase 3 design while Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level serves as the main decision variable. The value of this program will depend on whether the protocol converts biological rationale into a clinically interpretable and operationally credible readout.
PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add mechanism, development-status and sponsor context.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | JPRN-jRCT2031260310 |
| Official title | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 |
| Phase / status | Phase 3 / 募集前 |
| Intervention | Alixorexton |
| Sponsor | Alkermes, Inc. |
| Geography | Japan |
| Enrollment | 12 |
| Primary endpoint | Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level |
| Endpoint time frame | Not reported |
| Primary completion / readout proxy | 2027-04-16 |
Design and endpoint interpretation
The design should be read as an evidence architecture, not just a phase label. Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment. Enrollment of 12 participants across Japan shapes statistical precision, execution risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.
- Primary: Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level
- Primary: 覚醒維持検査（MWT）の平均睡眠潜時（MSL）のベースラインからWeek 12までの用量レベル別変化
Benchmark readouts in the surrounding field
- Long-term Safety and Efficacy of Extended-release Once-nightly Sodium Oxybate for Narcolepsy in Patients not Currently Taking an Oxybate (Phase 3): Cataplexy episodes(change from baseline) = -8.3 Point ( -12.1 to -4.6)
- 武田制药在2025年世界睡眠大会上公布针对1型发作性睡病 具有里程碑意义的Oveporexton（TAK-861）3期临床研究食欲素数据 (临床3期): ESS评分(第12周) = 85 % 达到; ESS评分(第12周) = 近85%的受试者与健康个体相当（≤10）。 % 达到
- Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025 (Phase 2): MWT(MSL change, LSM diff at week 6 vs. placebo) = –0.6 minutes ; MWT(MSL change, LSM diff at week 6 vs. placebo) = 24.1 minutes
These indexed results are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, treatment line, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.
Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset context: Alixorexton (Phase 3; OX2R)
Company & Deal Intelligence context: Alkermes, Inc. — https://www.alkermes.com
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes that connect activity with function, symptoms, survival or treatment burden.
- Sequencing evidence: comparative data after the most relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.
Bottom line
JPRN-jRCT2031260310 is a focused lens on Narcolepsy development. Its value will be determined by whether Alixorexton can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from existing benchmark readouts.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
